慢性腎臓病CKD　病態理解に基づいた予防と治療のあり方

出版社： メディカルレビュー社
著者：
発行日： 2009-10-10
分野： 臨床医学：内科  >  腎臓
ISBN： 9784779204074
電子書籍版： 2009-10-10 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

4,400 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,200 円(税込)

購入する

商品紹介

わずか30年程度の間に腎臓病の様相、臨床的意義は大きく変貌している。歴史の所産、進化の宿命として出現した慢性腎臓病CKDについて、その病態、予防、治療のあり方を理解するためのテキスト。

目次

  • 慢性腎臓病CKD　病態理解に基づいた予防と治療のあり方

    ―目次―

    Chapter 1　Overview
    　進化の宿命　strain vessel

    Chapter 2　腎障害の成因が多様化している
    　1．糖尿病
    　2．高血圧とCKD
    　3．動脈硬化症とCKD
    　4．肥満
    　5．睡眠時無呼吸症候群とCKD
    　6．メタボリックシンドローム
    　7．脂質異常症とCKD
    　8．高尿酸血症とCKD　
    　9．加齢とCKD

    Chapter 3　腎障害をいかに見出すか
    　1．日常診療における検尿の診かた
    　2．アルブミン尿、蛋白尿は何を語るか
    　3．腎機能の評価法
    　4．簡便な画像診断法

    Chapter 4　心腎脳連関：腎臓病は心血管病、全身疾患である
    　1．心臓と腎臓の機能的関連
    　2．心疾患、脳卒中とCKD
    　3．慢性腎臓病はなぜ心血管病の危険因子なのか
    　
    Chapter 5　包括的な診療の提案
    　1．生活習慣の改善
    　2．血圧管理、降圧目標
    　3．RAS阻害薬の使い方
    　4．RAS阻害薬以外の降圧薬の使い方
    　5．脂質管理
    　6．貧血の管理

    Chapter 6　あとがき
    　今後の展望

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Chapter2 腎障害の成因が多様化している

P.39 掲載の参考文献
1) National Kidney Foundation:K/DOQI clinical practice guidelines for chronic kidney disease:evaluation, classification, and stratification. Am J Kidney Dis 39 (2 Suppl 1):S1-S266, 2002
 
2) 日本腎臓学会 (編):第2章CKDの意義エビデンスに基づくCKD診療ガイドライン 2009. 東京医学社, 東京, 2009, pp17-27
 
3) 古家大祐:高血糖に起因する糖尿病性腎症の成因. 日本腎臓学会誌 49:470-473, 2007
 
4) 柏原直樹:糖尿病性腎症の基盤病態の理解と治療の考え方. 糖尿病の療養指導 2008. 療養指導士を育てるために. (日本糖尿病学会編) 東京, 診断と治療社, 40-45, 2008
 
5) 柏原直樹:糖尿病性腎症の病態と治療. 日本内科学会雑誌 97:614-620, 2008
 
6) 柏原直樹, 佐藤稔:分子病態. (特集:CKD-早期介入の意義と期待効果. 病因 病態) 日本臨牀 66:1671-1677, 2008
 
7) Ichihara A, Sakoda M, Mito-Kurauchi A, Itoh H:Activated prorenin as a therapeutic target for diabetic nephropathy. Diabetes Res Clin Pract 82(Suppl 1):S63-S66, 2008
 
8) 日本腎臓学会:糖尿病性腎症に関する合同委員会報告. 日本腎臓学会誌 44:1, 2002
 
9) 猪股茂樹, 羽田勝計, 守屋達美ほか:糖尿病性腎症の新しい早期診断基準. 糖尿病 48:757-759, 2005
 
10) 日本高血圧学会:第6章臓器障害を合併する高血圧. 3. 腎疾患. 高血圧治療ガイドライン 2009. ライフサイエンス出版, 東京, 2009, pp53-58
 
11) Viberti G, Wheeldon NM; Microalbuminuria Reduction with VALsartan (MARVAL) Study Investigators:Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus:a blood pressure-independent effect. Circulation 106:672-678, 2002
 
12) Shiga Microalbuminuria Reduction Trial (SMART) Group, Uzu T, Sawaguchi M, Maegawa H, Kashiwagi A:Reduction of microalbuminuria in patients with type 2 diabetes:the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care 30:1581-1583, 2007
PubMed
13) Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators:Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
 
14) Ruggenenti P, Fassi A, Ilieva AP, et al; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators:Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351:1941-1951, 2004
PubMed
15) Araki S, Haneda M, Sugimoto T, et al:Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes 54:2983-2987, 2005
PubMed
16) Andersen S, Brochner-Mortensen J, Parving HH; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group:Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care 26:3296-3302, 2003
 
17) Gaede P, Vedel P, Larsen N, et al:Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003
PubMed
P.49 掲載の参考文献
1) Klag MJ, Whelton PK, Randall BL, et al:Blood pressure and end-stage renal disease in men. N Engl J Med 334:13-18, 1996
 
2) Tozawa M, Iseki K, Iseki C, et al:Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension 41:1341-1345, 2003
PubMed
3) Bakris GL, Williams M, Dworkin L, et al:Preserving renal Function in adults with hypertension and diabetes:a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 36:646-661, 2000
 
4) Ogawa S, Takeuchi K, Mori T, et al:Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy. Hypertens Res 30:325-334, 2007
 
5) Ogawa S, Mori T, Nako K, et al:Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. Hypertension 47:699-705, 2006
PubMed
6) Kawabe K, Watanabe TX, Shiono K, Sokabe H:Influence on blood pressure of renal isografts between spontaneously hypertensive and normotensive rats, utilizing the F1 hybrids. Jpn Heart J 19:886-894, 1978
 
7) Cowley AW, Roman RJ, Fenoy FJ, Mattson DL:Effect of renal medullary circulation on arterial pressure. J Hypertens Suppl 10:Sl87-S193, 1992
 
8) Farrugia E, Lockhart JC, Larson TS:Relation between vasa recta blood flow and renal interstitial hydrostatic pressure during pressure natriuresis. Circ Res 71:1153-1158, 1992
PubMed
9) Taylor NE, Cowley Aw Jr:Effect of renal medullary H202 on salt-induced hypertension and renal injury. Am J Physiol Regul lntegr Comp Physiol 289:R1573-R1579, 2005
 
10) Mori T, O'Connor PM, Abe M, Cowley Aw Jr:Enhanced superoxide production in renal outer medulla of Dahl salt-sensitive rats reduces nitric oxide tubular-vascular cross-talk, Hypertension 49:1336-1341, 2007
PubMed
11) Mori T, Cowley Aw Jr, Ito S:Molecular mechanisms and therapeutic strategies of chronic renal injury:physiological role of angiotensin II-induced oxidative stress in medulla. J Pharmacol Sci 100:2-8, 2006
PubMed
12) Mori T, cowley Aw Jr:Renal oxidative stress in medullary thick ascending limbs produced by elevated Nac1 and glucose. Hypertension 43:341-346, 2004
 
13) Abe M, O'Connor n Kaldunski M, et al:Effect of sodium delivery on superoxide and nitric oxide in the medullary thick ascending limb. Am J Physiol Renal Physiol 291:F350-F357, 2006
 
14) Kobori H, Nangaku M, Navar LG, Nishiyama A:The intrarenal renin-angiotensin system:from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 59:251-287, 2007
 
15) Yoneda T, Takeda Y, Usukura M, et al:Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. Am J Hypertens 20:1329-1333, 2007
PubMed
16) Nagase M, Matsui H, Shibata S, et al:Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor:role of oxidative stress. Hypertension 50:877-883, 2007
PubMed
17) Nishiyama A, Yao L, Nagai Y, et al:Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 43:841-848, 2004
PubMed
18) Arima S, Kohagura K, Xu HL, et al:Nongenomic vascular action of aldosterone in the glomerular microcircularion. J Am Soc Nephrol 14:2255-2263, 2003
PubMed
19) Ichihara A, Kaneshiro Y, Takemitsu T, et al:Contribution of nonproteolytically activated prorenin in glomeruli to hypertensive renal damage. J Am Soc Nephrol 17:2495-2503, 2006
PubMed
20) Mori T, Cowley AW Jr:Role of pressure in angiotensin II-induced renal injury:chronic servo-control of renal perfusion pressure in rats. Hypertension 43:752-729, 2004
PubMed
21) Mori T, Polichnowski A, Glocka P, et al:High perfusion pressure accelerates renal injury in salt, sensitive hypertension. J Am Soc Nephrol 19:1472-1482, 2008
 
P.60 掲載の参考文献
1) 日本腎臓学会 (編):CKD 診療ガイド. 東京医学社, 東京, 2007
 
2) Ross R:Athcrosclerosis an inflammatory disease. N Engl J Med 340:115-126, 1999
PubMed
3) Hamirani Ys, Pandey S, Rivera JJ, et al:Markers of inflammation and coronary artery calcification:A systematic review. Atherosclerosis 201:1-7, 2008
 
4) 日本透析医学会 (編):図説わが国の慢性透析療法の現況 (2007年12月31日現在). 日本透析医学会, 東京, 2008
 
5) Keith DS, Nichols GA, Gullion CM, et al:Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern. Med 164:659-663, 2004
 
6) Schiffrin EL, Lipman ML, Mann JF:Chronic kidney disease:effects on the cardiovascular system. Circulation 116:85-97, 2007
PubMed
7) Kidney Disease Outcomes Quality Initiative (K/DOQI):K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43 (5 Suppl 1):S1-S290, 2004
 
8) Blacher J, Guerin AP, Pannier B, et al:Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99:2434-2439, 1999
PubMed
9) Fox CS, Larson MG, Leip EP, et al:Predictors of new-onset kidney disease in a community-based population. JAMA 291:844-850, 2004
 
10) Yamagata K, Iseki K, Nitta K, et al:chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol 12:1-8, 2008
PubMed
11) 日本動脈硬化学会 (編):動脈硬化性疾患予防ガイドライン 2007 年版. 協和企画, 東京, 2007
 
12) 阿部倫明, 伊藤貞嘉:1. 急性賢不全. 5) 腎梗塞. 血栓と循環 16:292-298, 2008
 
13) Meyrier A, Hill GS, Simon P:Ischemic renal diseases:new insights into old entities. Kidney Int 54:2-13, 1998
PubMed
14) Thadhani R, Pascual M, Nickeleit V, et al:Preliminary description of focal segmental glomerulosclerosis in patients with renovascular disease. Lancet 347:231-233, 1996
PubMed
15) Greenberg A, Bastacky SI, Iqbal A, et al:Focal segmental glomerulosclerosis associatcd with nephrotic syndrome in cholestcrol atheroembolism:clinicopathological correlations. Am J Kidney Dis 29:334-344, 1997
PubMed
16) Bohle A, Muller GA, Wehrmann M, et al:Pathogenesis of chronic renal failure in the primary glomerulopathies, renal vasculopathies, and chronic interstitial nephritides. Kidney Int 49 (Suppl 54):S2-S9, 1996
 
17) Safian RD, Textor SC:Renal-artery stenosis. N Engl J Med 344:431-442, 2001
PubMed
18) Textor SC:Progressive hypertension in a patient with "incidental" renal artery stenosis. Hypertension 40:595-600, 2002
 
19) Textor SC:Pitfalls in imaging for renal artery stenosis. Ann Intern Med 141:730-731, 2004
PubMed
20) Rihal CS, Textor SC, Breen JF, et al:Incidental renal artery stenosis among a prospective cohort of hypertensive patients undergoing coronary angiography. Mayo Clin Proc 77:309-316, 2002
PubMed
21) Hansen KJ, Edwards MS, Craven TE et al:Prevalence of renovascular disease in the elderly:a population-based study. J Vasc Surg 36:443-451, 2002
PubMed
22) Rundback JH, Murphy TP, Cooper C, Weintraub JL:Chronic renal ischcmia:pathophysiologic mechanisms of cardiovascular and renal disease. J Vasc Interv Radiol 13:1085-1092, 2002
 
23) Vachharajani TJ, Dacie JE, Yaqoob MM, et al:Detection of occult renovascular disease in unexplained chronic kidney disease. Int Urol Nephrol 37:793-796, 2005
PubMed
24) Weiss JS, Sumpio BE:Review of prevalence and outcome of vascular disease in patients with diabetes mellitus. Eur J Vasc Endovasc Surg 31:143-150, 2006
PubMed
25) Schreiber MJ, Pohl MA, Novick AC:The natural history of atherosclerotic and fibrous renal artery disease. Urol Clin North Am 11:383-392, 1984
PubMed
26) Guzman RP, Zierler RE, Isaacson JA, et al:Renal atrophy and arterial stenosis. A prospectivc study with duplex ultrasound. Hypertension 23:346-350, 1994
PubMed
27) Hirsch AT, Haskal ZJ, Hertzer NR, et al:ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic):a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease):endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute;Society for Vascular Nursing; Trans Atlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 113:e463-e654, 2006
 
28) Yudd M, Llach F:Vascular complications involving the renal vessels. In:Brenner & Recto's the Kidney. 6th ed. (Brenner BM ed) W.B. Saunders, Philadelphia, 2000, pp1537-1562
 
29) Nicholas GG, DeMuth WE Jr:Treatment ofrenal artery embolism. Arch Surg 119:278-281, 1984
 
30) Hayashida N, Murayama H, Pearce Y, et al:Shaggy aorta syndrome after acute artcrial macroembolism:report of a case. Surg Today 34:354-356, 2004
PubMed
31) 阿部倫明:m章腎硬化症. Q1高血圧 動脈硬化による賢障害にはどのようなものがあるか? 専門医のための薬物療法 Q&A 腎臓. (富野康日己, 柏原直樹編) 中外医学社, 東京, 2007, pp213-215
 
32) Gusbeth-Tatomir P, Covic A:Causes and consequences of increased arterial stiffness in chronic kidney disease patients. Kidney Blood Press Res 30:97-107, 2007
PubMed
33) Makita Z, Bucala R, Rayfield EJ, et al:Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 343:1519-1522, 1994
PubMed
34) Miyata T, van Ypersele de Strihou, Kurokawa K, Baynes JW:Alterations in nonenzymatic biochemistry in uremia:origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 55:389-399, 1999
PubMed
35) Odani H, Shinzato T, Matsumoto Y, et al:Increase in three α, β-dicarbonyl compound levels in human uremic plasma:specific in vivo determination of intermediates in advanced Maillard reaction. Biochem Biophys Res Commun 256:89-93, 1999
 
36) Hipkiss AR:Dietary restriction, glycolysis, hormesis and ageing. Biogerontology 8:221-224, 2007
PubMed
37) Verzijl N, DeGroot J, Thorpe SR, et al:Effect of collagen turnover on the accumulation of advanced glycation end products. J Biol Chem 275:39027-39031, 2000
PubMed
38) Konova E, Baydanoff S, Atanasova M, Velkova A:Age-related changes in the glycation of human aortic elastin. Exp Gerontol 39:249-254, 2004
PubMed
39) Yavuz A, Tetta C, Ersoy FE et al:Uremic toxins:a new focus on an old subject. Semin Dial 18:203-211, 2005
 
40) Miyazaki H, Matsuoka H, Cooke JP, et al:Endogenous nitric oxide synthase inhibitor:a novel marker of atherosclerosis. Circulation 99:1141-1146, 1999
PubMed
41) Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH:The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 44:638-642, 1993
PubMed
42) Shepherd J, Kastelein JJ, Bittner V, et al; TNT (Treating to New Targets) Investigators:Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease:the TNT (Treating to New Targets) study. J Am Coll Cardiol 51:1448-1454, 2008
PubMed
43) Uber A, Rettig R:Pathogenesis of primary hypertension-Lessons from renal transplantation studies. Kidney Int Suppl 55:S42-S45, 1996
PubMed
44) Curtis JJ, Luke RG, Dustan HP et al:Remission of essential hypertension after renal transplantation. N Engl J Med 309:1009-1015, 1983
PubMed
45) Gates PE, Tanaka H, Hiatt WR, Seals DR:Dietary sodium restriction rapidly improves large clastic artery compliance in older adults with systolic hypertension. Hypertension 44:35-41, 2004
 
46) Johnson RC, Leopold JA, Loscalzo J:Vascular calcification:pathobiological mechanisms and clinical implications. Circ Res 99:1044-1059, 2006
PubMed
47) Savage T, Clarke AL, Giles M, et al:Calcified plaque is common in the carotid and femoral arteries of dialysis patients without clinical vascular disease. Nephrol Dial Transplant 13:2004-2012, 1998
PubMed
48) Cola C, Almeida M, Li D, et al:Regulatory role of endothelium in the expression of genes affecting arterial calcification. Biochem Biophys Res Commun 320:424-427, 2004
PubMed
49) Moe SM, Duan D, Doehle BB et al:Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int 63:1003-1011, 2003
 
50) Mizobuchi M, Ogata H, Hatamura I, et al:Up-regulation of Cbfa1 and Pit-1 in calcified artery of uraemic rats with severe hyperphosphataemia and secondary hyperparathyroidism. Nephrol Dial Transplant 21:911-916, 2006
PubMed
P.68 掲載の参考文献
1) Iseki K, Ikemiya Y, Kinjo K, et al:Body mass index and the risk of development of end-stage renal disease in ascreened cohort. Kidney Int 65:1870-1876, 2004
PubMed
2) Gelber RP, Kurth T, Kausz AT, et al:Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis 46:871-880, 2005
PubMed
3) Kramer H, Luke A, Bidani A, et al:Obesity and prevalent and incident CKD:the Hypertension Detection and Follow-Up Program. Am J Kidney Dis 46:587-594, 2005
PubMed
4) 李利文, 小川晋, 伊藤貞嘉ほか:糖尿病性腎症に対する肥満の影響. 東北医学雑誌 112:125-130, 2001
 
5) de Jong PE, Verhave JC, Pinto-Sietsma SJ, Hillege HL; PREVEND study group:Obesity and target organ damage:the kidney. Int J Obes Relat Metab Disord 26 (Suppl. 4):S21-S24, 2002
 
6) Weisinger JR, Kempson RL, Eldridge FL Swenson RS:The nephrotic syndrome:a complication of massive obesity. Ann Intern Med 81:440-447, 1974
PubMed
7) Cohen AH:Massive obesity and the kidney. A morphologic and statistical study. Am J Pathol 81:117-130, 1975
PubMed
8) Pinto-Sietsma SJ, Navis G, Janssen WM, et al; PREVEND Study Group:A central body fat distribution is related to renal function impairment, even in lean subjects. Am J Kidney Dis 41:733-741, 2003
 
9) Wolf G, Chen S, Ziyadeh FN:From the periphery of the glomerular capillary wall toward the center of disease:podocyte injury comes of age in diabetic nephropathy. Diabetes 54:1626-1634, 2005
 
10) Henegar JR, Bigler SA, Henegar LK, et al:Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 12:1211-1217, 2001
 
11) Kambham N, Markowitz GS, Valeri AM, et al:Obesity-related glomerulopathy:an emerging epidemic. Kidney Int 59:1498-1509, 2001
PubMed
12) Jiang T, Liebman SE, Lucia MS, et al:Role of altered renal lipid metabolism and the sterol regulatory element binding proteins in the pathogenesis of age-related renal disease. Kidney Int:68:2608-2620, 2005.
PubMed
13) Wang Z, Jiang T, Li J, et al:Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes 54:2328-2335, 2005
 
14) Mori T, Cowley AW Jr:Renal oxidative stress in medullary thick ascending limbs produced by elevated NaC1 and glucose. Hypertension 43:341-346, 2004
 
15) Nakanishi K, Mattson DL, Cowley Aw Jr:Role of renal medullary blood flow in the development of L-NAME hypertension in rats. Am J Physiol 268 (2 Pt 2):R317-R323, 1995
 
16) Zou AP, Wu F, Cowley AW Jr:Protective effect of angiotensin II-induced increase in nitric oxide in the renal medullary circulation. Hypertension 31:271-276, 1998
PubMed
17) Abe M, 0'Connor P, Kaldunski M, et al:Effect of sodium delivery on superoxide and nitric oxide in the medullary thick ascending limb. Am J Physiol Renal Physiol 291:F350-F357, 2006
 
18) Wu Y, Liu Z, Xiang Z, et al:Obesity-related glomerulopathy:insights from gene expression profiles of the glomeruli derived from renal biopsy samples. Endocrinology 147:44-50, 2006
 
19) Rohrwasser A, Morgan T, Dillon HF et al:Elements of a paracrine tubular renin-angiotensin system along the entire nephron. Hypertension 34:1265-1274, 1999
PubMed
20) Suzaki Y, Ozawar Y, Kobori H:Intrarenal oxidative stress and augmented angiotensinogen are precedent to renal injury in Zucker diabetic fatty rats. Int J Biol Sci 3:40-46, 2006
 
21) Brezniceanu ML, Liu E Wei CC, et al:Catalase overexpression attenuates angiotensinogen expression and apoptosis in diabetic mice. Kidney Int 71:912-923, 2007
 
22) Hodroj W, Legedz L, Foudi N, et al:lncreased insulin-stimulated expression of arterial angiotensinogen and angiotensin type 1 receptor in patients with type 2 diabetes mellitus and atheroma. Arterioscler Thromb Vasc Biol 27:525-531, 2007
 
23) Hsieh TJ, Fustier P, Zhang SL, et al:High glucose stimulates angiotensinogen gene expression and cell hypertrophy via activation of the hexosaminc biosynthesis pathway in rat kidney proximal tubular cells. Endocrinology 144:4338-4349, 2003
PubMed
24) Liu BF, Miyata S, Hirota Y, et al:Methylglyoxal induces apoptosis through activation of p38 mitogen-activated protein kinase in rat mesangial cells. Kidney lnt 63:947-957, 2003
 
25) 小川晋:糖尿病性腎症における降圧療法の意義. 糖尿病診療マスター 6 (4):394-400, 2008
 
26) Ito S, Amin J, Ren Y, et al:Heterogeneity of angiotensin action in renal circulation. Kidney Int Suppl 63:S128-S131, 1997
PubMed
27) Chappel MC, Ferrario CM:ACE and ACE2:their role to balance the expression of angiotensin II and angiotensin-(1-7). Kidney lnt 70:8-10, 2006
 
28) Santos RA, Ferreira AJ, Simoes E Silva AC:Recent advances in the angiotensin-converting enzyme 2-angiotensin (1-7)-Mas axis. Exp Physiol 93:519-527, 2008
PubMed
29) Su Z, Zimpelmann J, Burns KD:Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Int 69:2212-2218, 2006
PubMed
30) Gallagher PE, Ferrario CM, Tallant EA:MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides. Am J Physiol Cell Physiol 2008 Sep 3. (Epub ahead of print)
 
31) Guo YJ, Li WH, Wu R, et al:ACE2 overexpression inhibits angiotensin II-induced monocyte chemoattractant protein-1 expression in macrophages. Arch Med Res 39:149-154, 2008
PubMed
32) Keidar S, Strizevsky A, Raz A, Gamliel-Lazarovich A:ACE2 activity is increased in monocyte-derived macrophages from prehypertensive subjects. Nephrol Dial Transplant 22:597-601, 2007
PubMed
33) Santos SH, Fernandes LR, Mario EG, et al:Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes 57:340-347, 2008
PubMed
34) Gupte M, Boustany-Kari CM, Bharadwaj K, et al:ACE2 is expressed in mouse adipocytes and regulated by a high-fat diet. Am J Physiol Regul Integr Comp Physiol 295:R781-R788, 2008
PubMed
35) Tikellis C, Bialkowski K, Pete J, et al:ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes 57:1018-1025, 2008
PubMed
36) Shao Y, He M, Zhou L, et al:Chronic angiotensin (1-7) injection accelerates STZ-induced diabetic renal injury. Acta Pharmacol Sin 29:829-837, 2008
PubMed
37) Montani JP, Antic V, Yang Z, Dulloo A:Pathways from obesity to hypertension:from the perspective of a vicious triangle. Int J Obes Relat Metab Disord (Suppl 2):S28-S38, 2002
 
38) Krikken JA, Lely AT, Bakker SJ, Navis G:The effect of a shift in sodium intake on renal hemodynamics is determined by body mass index in healthy young men. Kidney Int 71:260-265, 2007; Epub 2006 Nov 8
 
39) Ribstein J, du Cailar G, Mimran A:Combined renal effects of overweight and hypertension. Hypertension 26:610-615, 1995
PubMed
40) Chagnac A, Weinstein T, Korzets A, et al:Glomerular hemodynamics in severe obesity. Am J. Physiol Renal Physiol 278:F817-F822, 2000
PubMed
41) Bosma RJ, van der Heide JJ, Oosterop EJ, et al:Body mass index is associated with altered renal hemodynamics in non-obese healthy subjects. Kidney Int 65:259-265, 2004
PubMed
42) Parvanova AI, Trevisan R, Iliev IP et al:Insulin resistance and microalbuminuria:a cross-sectional, case-control study of 158 patients with type 2 diabetes and different degrees of urinary albumin excretion. Diabetes 55:1456-1462, 2006
PubMed
43) Pistrosch F, Herbrig K, Kindel B, et al:Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 54:2206-2211, 2005
PubMed
44) Chagnac A, Weinstein T, Herman M, et al:The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 14:1480-1486, 2003
PubMed
45) Morales E, Valero MA, Leon M, et al:Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 41:319-327, 2003
PubMed
46) Tran HA:Reversible obesity-related glomerulopathy following weight reduction. Med J Aust 184:367, 2006
PubMed
47) Kabir M, Catalano KJ, Ananthnarayan S, et al:Molecular evidence supporting the portal theory:a causative link between visceral adiposity and hepatic insulin resistance. Am J Physiol Endocrinol Metab 288:E454 E461, 2005
 
48) Wang Z, Jiang T, Li J, et al:Regulation of renal lipid metabolism, lipid accumlation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes 54:2328-2335, 2005
 
49) Taniguchi CM, Ueki K, Kahn R:Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. J Clin Invest 115:718-727, 2005
PubMed
50) Trayhurn P, Wood IS:Adipokines:inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92:347-355, 2004
PubMed
51) Fain JN, Tichansky DS, Madan AK:Transforming growth factor beta1 release by human adipose tissue is enhanced in obesity. Metabolism 54:1546-1551, 2005
 
52) Saiki K, Koide N, Watanabe F, et al:Suppression of lipoprotein lipase expression in 3T3-L1 cells by inhibition of adipogenic differentiation through activation of the renin-angiotensin system. Metabolism 57:1093-1100, 2008
 
53) Zheng Y, Yamada H, Sakamoto K, et al:Roles of insulin receptor substrates in insulin-induced stimulation of renal proximal bicarbonate absorption. J Am Soc Nephrol 16:2288-2295, 2005
PubMed
P.78 掲載の参考文献
1) Kimmel PL, Miller G, Mendelson WB:Sleep apnea syndrome in chronic renal disease. Am J Med 86:308-314, 1989
PubMed
2) Auckley DH, Schmidt-Nowara W Brown LK:Reversal of sleep apnea hypopnea syndrome in end-stage renal disease after kidney transplantation. Am J Kidney Dis 34:739-744, 1999
PubMed
3) Elias RM, Castro MC, de Queiroz EL, et al:Obstructive Sleep Apnea in Patients on Conventional and Short Daily Hemodialysis. Am J Nephrol 29:493-500, 2008
PubMed
4) Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee:The seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure:the JNC 7 report. JAMA 289:2560-2572, 2003
 
5) Becker HF, Jerrentrup A, Ploch T, et al:Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 107:68-73, 2003
PubMed
6) Akashiba T, Minemura H, Yamamoto H, et al:Nasal continuous positive airway pressure changes blood pressure "non-dippers"to"dippers" in patients with obstructive sleep apnea. Sleep 22:849-853, 1999
PubMed
7) Ohtake T, Kobayashi S, Moriya H, et al:High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy:an angiographic examination. J Am Soc Nephrol 16:1141-1148, 2005
PubMed
8) Shahar E, Whitney CW Redline S, et al:Sleep-disordered breathing and cardiovascular disease:cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 163:19-25, 2001
 
9) Sorajja D, Gami AS, Somers VK, et al:Independent association between obstructive sleep apnea and subclinical coronary artery disease. Chest 133:927-933, 2008
PubMed
10) Javaheri S, Parker TJ, Liming JD, et al:Sleep apnea in 81 ambulatory male patients with stable heart failure. Types and their prevalences, consequences, and presentations. Circulation 97:2154-2159, 1998
PubMed
11) Harsch IA, Schahin SP, Bruckner K, et al:The effect of continuous positive airway pressure treatment on insulin sensitivity in patients with obstructive sleep apnoea syndrome and type 2 diabetes. Respiration 71:252-259, 2004
PubMed
12) Tsioufis C, Thomopoulos C, Dimitriadis K, et al:Association of obstructive sleep apnea with urinary albumin excretion in essential hypertension:a cross-sectional study. Am J Kidney Dis 52:285-293, 2008
PubMed
13) Wada M, Nagasawa H, Iseki C, et al:Cerebral small vessel disease and chronic kidney disease (CKD):results of a cross-sectional study in community-based Japanese elderly. J Neurol Sci 272:36-42, 2008
PubMed
14) Arzt M, Young T, Finn L, et al:Association of sleep-disordered breathing and the occurrence of stroke. Am J Respir Crit Care Med 172:1447-1451, 2005
PubMed
P.85 掲載の参考文献
1) Taal MW, Brcnner BM:Predicting initiation and progression of chronic kidney discasc:Devcloping renal risk scores. Kidney Int.:70:1694-1705, 2006
 
2) Fox CS, Larson MG, Leip EP, et al:Predictors of new-onset kidney disease in a community-based population. JAMA 1291:844-850, 2004
 
3) Isomaa B, Almgren P, Tuomi T, et al:Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683-689, 2001
PubMed
4) Lakka HM, Laaksonen DE, Lakka TA, et al:The metabolic syndrome and total and cardiovascular disease mortality in middlc-aged men. JAMA 288:2709-2716, 2002
PubMed
5) Chen J, Muntner P, Hamm LL, et al:The metabolic syndrome and chronic kidney disease in U. S. adults. Ann lntern Med l 40:167-174, 2004
 
6) Kurella M, Lo JC, Chertow GM:Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. Am Soc Nephrol 16:2134-2140, 2005
PubMed
7) Tanaka H, Shiohira Y, uezu Y, et al:Metabolic syndrome and chronic kidncy discase in Okinawa, Japan. Kidnept Int 69:369-374, 2006
 
8) Ninomiya T, Kiyohara Y, Kubo M, et al:Metabolic syndrome and CKD in a general Japanese population:the Hisayama Study. Am j Kidney Dis 48:383-391, 2006
 
9) Tozawa M, Iseki C, Tokashiki K, et al:Metabolic syndrome and risk of developing chronic kidney discase in Japanese adults. Hypertens Res 30:937-943, 2007
 
10) Kitiyakara C, Yamwong S, Chcepudomwit S, et al:The metabolic syndrome and chronic kidney disease in a Southeast Asian cohort.Kidnay Int:693-700, 2007
 
11) Chen J, Gu D, chen cs, et al:Association between the mctabolic syndrome and chronic kidncy disease in Chinese adults. Nephrol Dial Transplant 22:1100-1106, 2007
PubMed
12) Lucove J, vupputuri S, Heiss G, et al:Metabolic syndrome and the devclopment of CKD in Amcrican Indians:the Strong Heart Study. . Am J Kidney Dis 51:21-28, 2008
PubMed
13) Rashidi A, Ghanbarian A, Azizi F:Are patients who have metabolic syndrome without diabetes at risk for developing chronic kidney diseasc-Evidence based on data from a large cohort screening popuiation. Clin J Am Soc Nephrol 2:976-983, 2007
 
14) Lea J, cheek D, Thornley-Brown D, et al; AASK Study Investigators:Metabolic syndrome, Proteinuria, and the risk ofprogressive CKD in hypertensive African Americans. Am J Kidney Dis 51:732-740, 2008
 
15) Palaniappan L, Carnethon M, Fortmann SP:Association between microalbuminuria and the metabolic syndrome:NHANES III. Am J.Hypertens 16:952-958, 2003
PubMed
16) Hao Z, Konta T, Takasaki S, et al:The association between microalbuminuria and metabolic syndrome in the general population in Japan:the Takahata study,. Intern Med 46:341-346, 2007
PubMed
17) Steinberg HO, Chakcr H, Lcaming R, et al:Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndromc ofinsulin resistance. J Clin Invest 97:2601-2610, 1996
 
18) Lteif AA, Han K, Mather KI:obesity insulin resistance, and the metabolic syndrome:determinants of endothelial dysfunction in whites and blacks. Circulation 112:32-38, 2005
 
19) Rask-Madsen C, King GL:Mechanisms of Disease:endothelial dysfunction in insulin resistance and diabetes. Nat Clin, Pract Endocrinol Metab 3:46-56, 2007
PubMed
20) Ochodnicky P, Henning RH, van Dokkum RP, de Zceuw D:Microalbuminuria and endothelial dysfunction:emerging targetsfor primary prevention of end-organ damage. J Cardiovasc Pharmacol 47 (Suppl 2):Sl51-S162, 2006
 
21) Kambham N, Markowitz GS, Valeri AM, et al:Obesity-related glomcrulopathy:an cmerging epidemic. Kidney Int 59:1498-1509, 2001
PubMed
22) Wahba IM, Mak RH l Obesiry and obesity-initiated metabolic syndrome:mcchanistic links to chronic kidney-desease. Clin J Am Soc Nephrol 2:550-562, 2007
 
23) Karalliedde J, viberti G:Evidence fbr renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertcnsion and diabetes. J Hum Hypertens 20:239-253, 2006
 
24) de Vinuesa SG, Goicoechea M, Kanter J, et al:Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease:effects ofangiotensin II blockade. J Am Soc Nephrol 17 (12 Suppl 3):S206-S212, 2006
 
25) Namikoshi T, Tomita N, Satoh M, et al:Olmesartan ameliorates renovascular injury and oxidative stress in Zucker obese rats enhanced by dietary protein. Alm J Hypertens 20:1085-1091, 2007
 
26) Sarafidis PA, Bakris GL:Protection of the kidney by thiazolidinediones:an assessment from bench to bedside. Kidney Int 70:1223-1233, 2006
PubMed
27) Kadowaki T, Yamauchi T, Kubota N, et al:Adiponectin and adiponectin receptors in insulin resistance, diabetes, and thc metabolic syndrome. J Clin. Invest 116:1784-1792, 2006
 
28) Sharma K, Ramachandrarao s, Qiu G, et al:Adiponectin regulates albuminuria and podocytc function in mice. J Clin Invest 118:1645-1656, 2008
PubMed
29) Szapary PO, Bloedon LT, Samaha FE et al:Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabctic patients with metabolic syndrome. Arterioscler Thomb Vasc Biol 26:182-188, 2006
 
30) Namikoshi T, Satoh M, Tomita N, et al:Pioglitazone ameliorates endothelial dysfunction in obese rats with nephropathy. Biochem Biophys Res Commun 361:835-840, 2007
PubMed
P.93 掲載の参考文献
1) Moorhead JE Chan MK, El-Nahas M, Varghese Z:Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2:1309-1311, 1982
 
2) Beaumont JL, Carlson LA, cooper GR, et al:classiffcation of hyperlipidaemias and hyperlipoproteinaemias. Bull World Health Organ 43 891-915, 1970
PubMed
3) Schaeffner ES, Kurth T, Curhan GC, et al:Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 14:2084-2091, 2003
 
4) Muntner P, coresh J, Smith Jc, et al:Plasma lipids and risk of developing renal dysfunction:the athcrosclerosis risk in communities study. Kidney Int 58:293-301, 2000
PubMed
5) Appel GB, Radhakrishnan J, Avram MM, et al; RENAAL Study:Analysis of metabolic paramcters as predictors of risk in the RENAAL stud. Diabetes Care 26:1402-1407, 2003
 
6) Ravid M, Brosh D, Ravid-Safran D, et al:Main risk factors for nephropathy in rype 2 diabetes mellitus are plasma eholestcrol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 158:998-1004, 1998
 
7) Fagot-Campagna A, Nelson RG, Knowler WC, et al:Plasma lipoproteins and the incidence of abnormal excretion of albumin in diabetic American Indians:the Strong Heart Study. Diabetologia 41:1002-1009, 1998
PubMed
P.100 掲載の参考文献
2) Mazzali M, Hughes J, Kim YG, et al:Elevated uric acid increases blood pressurc in the rat by a novel crystal-independent mechanism. Hypertension 38:1101-1106, 2001
 
3) Kang DH, Nakagawa T, Feng L, et al:A role for uric acid in the progression of renal disease. J Am Soc Nephrol 13:2888-2897, 2002
 
4) Sinchez-Lozada LG, Tapia E, Avila-Casado C, et al:Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 283:F1105-F1110, 2002
 
5) Nakagawa T, Mazzali M, Kang DH, et al:Hyperuricemia causes glomerular hypcrtrophy in the rat. Am J Nephrol 23:2-7, 2003
PubMed
6) Mazzali M, Kanellis J, Han L, et al:Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 282:F991-F997, 2002
PubMed
7) Kanellis J, Watanabe s, Li JH, et al:Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenasc-2. Hypertension 41:1287-1293, 2003; Epub 2003 May 12
 
8) Khosla UM, Zharikov S, Finch JL, et al:Hyperuricemia induces endothelial dysfunction. Kidney int 67:1739-1742, 2005
PubMed
9) Ohno I, Hosoya T, Gomi H, et al:Serum uric acid and renal prognosis in patients with IgA nephropathy. Nephron 87:333-339, 2001
PubMed
10) Myllymaki J, Honkanen T, Syrjanen J, et al:uric acid correlates with the severity of histopathological parameters in IgA nephropathy.Nephrol Dial Transplant 20:89-95, 2005; Epub 2004 Nov 30
 
11) Obermayr RP, Temml C, Gutj ahr G, et al:Elevated Uric Acid lncreases the Risk for Kidney Diseasc. J Am Soc Nephrol 200 8 Sep 17 [Epub ahead of print]
 
12) Suliman ME, Johnson RJ, Garcia-Lopez E, et al:J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis 48:761-771, 2006
PubMed
13) Choi HK, Curhan G:Independent impact of gout on mortality and risk for coronary heart disease. Circulation 116:894-900, 2007; Epub 2007 Aug 13
 
14) Krishnan E, Baker JE Furst DE, schumacher HR:Gout and the risk of acute myocardial infarction. Arthritis Rheum 54:2688-2696, 2006
 
15) Bos MJ, Koudstaal PJ, Hofman A, et at:Uric acid is a risk factor for myocardial infarction and stroke:the Rotterdam study. Stroke 37:1503-1507, 2006; Epub 2006 May 4
 
l) 細谷龍男:高尿酸性腎症 (痛風腎). 内科学 (第九版) (杉本恒明, 矢崎義雄編) 朝倉書店, 東京, 2007, pp1225-1226
 
P.108 掲載の参考文献
1) Terasaki PI, Cecka JM, Gjcrtson Dw:Impact analysis:a method for evaluating the impact of factors in clinical renal transplantation. Clin Transpl 437-441, 1998
 
2) Ferlicot S, Durrbach A, Ba N, et al:The role of replicative senescence in chronic allograf nephropathy. Hum Pathol 34:924-928, 2003
 
3) Chkhotua A, Shohat M, Tobar A, et al:Replicative senescence in organ transplantation-mechanisms and significance. Transpl Immunol 9:165-171, 2002
PubMed
4) Ogiu N, Nakamura Y, Ijiri I, et al:Astatistical analysis of the internal organ weights of normal Japanese people. Healthy Phys 72:368-383, 1997
 
5) Griffiths GJ, Robinson KB, Cartwright GO, Mclachlan MS:Loss ofrenal tissue in the elderly. Br J Radiol 49:111-117, 1976
 
6) Darmady EM, Offer J, woodhouse MA:The parameters of the ageing kidney. J Pathol 109:195-207, 1973
 
7) Kaplan C, Pasternack B, Shah H, Gallo G:Age-related incidcnce of sclerotic glomeruli in human kidneys. Am J Pathol 80:227-234, 1975
PubMed
8) MacCallum DB:The bearing of degenerating glomeruli on the problem of the vascular supply of the mammalian kidney, . Am J Anat 65:69-103, 1939
 
9) Takazakura E, Sawabu N, Handa A, et al:Intrarenal vascular changes with age and disease. Kidney Int 2:224-230, 1972
PubMed
10) Coresh J, Astor BC, Greene T, et al:Prevalence of chronic kidney disease and decreased kidney function in the adult US population:Third National Health and Nutrition Examination Survey.Am J. Kidney Int 41:1-12, 2003
 
11) Lindeman RD, Tobin J, Shock NW:Associarion between blood pressure and the rate of decline in renal function with age. Kidney Int 26:861-868, 1984
 
12) Lindeman RD, Tobin J, Shock NW:Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 33:278-285, 1985
 
13) Sesso R, Prado F, Vicioso B, Ramos LR:Prospective study of progression of kidney dysfunction in community-dwelling older adults. Nephrology 13:99-103, 2008
PubMed
14) Ognibene A, Mannucci E, Caldini A, et al:Cystatin C reference values and aging. Clin Biochem 39:658-661, 2006
PubMed
15) Zhou XJ, Rakheja D, YU X, et al:The aging kidney. Kidneor. lnt 74:710-720, 2008
 
16) Sands JM:Urine-concentrating ability in the aging kidney. Sci Aging Knowledge Environ 2003:PE15, 2003
PubMed
17) Faull CM, Holmes C, Baylis PH:Water balance in elderly people:is there a deficiency of vasopressin? Age Ageing 22:114-120, 1993
 
18) Epstein M, Hollenberg NK:Age as a determinant of renal sodium conservation in normal man. J Lab Clin Med 87:411-417, 1976
 
19) Perazella MA, Mahnensmith RL:Hyperkalemia in the elderly:drugs exacerbate impaired potassium homcostasis.J Gen Intern Med 12:646-656, 1997
PubMed
20) Weidmann P, De Myttenaere-Bursztein S, Maxwell MH, de Lima J:Effect of aging on plasma renin and aldosterone in normal man. Kianey Int 8:325-333, 1975
PubMed
21) Morishita R, Higaki J, Mikami H, et al:Effect of aging on the renin angiotensin sysrem in patients with renovascular hypertension. Methods Find Exp Clin Pharmacol 14:17-21, 1992
 
22) Ishikawa S, Fujita N, Fujisawa G, et al:Involvement of arginine vasopressin and renal sodium handling in pathogenesis ofhyponatremia in elderly patients. Endocr J 43:101-108, 1996
 
23) Pollack JA, Skvorak Jp, Nazian SJ, et al:Alterations in atrial natriuretic peptide (ANP) secretion and renal effects in aging. J Gerontol A Biol Sci Med Sci 52:B196-B202, 1997
PubMed
24) Adler S, Lindeman RD, Yiengst MJ, et al:Effect of acute acid loading on urinary acid excretion by the aging human kidney. J Lab Clin Med 72:278-289, 1968
 
25) Ershler WB, Sheng S, McKelvey J, et al:Serum erythropoietin and aging:a longitudinal analysis.J Am Geriatr Soc 53:1360-1365, 2005
PubMed
26) Carpenter MA, Kendall RG, 0:Brien AE, et al:Reduced erythropoietin response to anaemia in elderly patients with normocytic anaemia. Eur J Haematol 49:119-121, 1992
 
27) Sherman SS, Hollis Bw, Tobin JD:Vitamin D status and related parameters in a healthy population:the effects of age, sex, and season. J Clin Endocrinol Metab 71:405-413, 1990
 
28) Amann K, Ritz E:Cardiovascular abnormalities in ageing and in uraemia only analogy or shared pathomechanisms? Nephrol Dial Transplant 13 (Suppl 7):S6-S11, 1998
PubMed
29) Beckman KB, Ames BN:The free radical theory of aging matures. Physiol Rev 78:547-581, 1998
PubMed
30) Chade AR, Lerman A, Lerman LO:Kidney in early atherosclerosis. Hypertension 45:1042-1049, 2005
PubMed
31) Reckelhoff JF, Kanji V, Racusen LC, et al:Vitamin E ameliorates enhanced renal lipid peroxidation and accumulation of F2-isoprostanes in aging kidneys. J Am Soc Nephrol 274 (3 Pt 2):R767-R774, 1998
 
32) Vlassara H:Protein glycation in the kidney:role in diabetes and aging. Kidnay Int 49:1795-1804, 1996
 
33) Tanaka T, Kato H, Kojima I, et al:Hypoxia and exprcssion of hypoxia-inducible factor in the aging kidney. J Gerontol A Biol Sci Med Sci 61:795-805, 2006
 
34) Melk A, Ramassar V, Helms LM, et al:Telomere shortening in kidneys with age. J Am Soc Nephrol 11:444-453, 2000
 
35) Kuro-o M:Endocrine FGFs and Klothos:emerging concepts. Trends Endocrinol Metab 19:239-245, 2008
 
36) Kuro-o M:Klotho as a regulator of oxidative stress and senescence. Biol Chem 389:233-241, 2008
PubMed
37) Mitobe M, Yoshida T, Sugiura H, et al:Oxidative stress decreases klotho expression in a mouse kidney cell line. Nephron Exp Nephrol 101:e67-e74, 2005
 
38) Saito K, Ishizaka N, Mitani H, et al:Iron chelation and a free radical scavenger suppress angiotensin II, induced downregulation of klotho, an anti aging gene, in rat. FEBS Lett 551:58-62, 2003
 
39) Nabeshima Y:Klotho:a fundamental regulator of aging. Ageing Res Rev 1:627-638, 2002
PubMed
40) Baylis C:Age-dependent glomerular damage in the rat. Dissociation between glomerular injury and both glomerular hypertension and hypertrophy. Male gender as a primary risk factor. J Clin Invest 94:1823-1829, 1994
PubMed
41) Elliot SJ, Karl M, Berho M, et al:Estrogen deficiency accelerates progression of glomerulosclerosis in susceptible mice.Am J Pathol 162:1441-1448, 2003
PubMed
42) Kobayashi S, Moriya H, Aso K, Ohtake T:Vitamin E-bonded hemodialyzer improves atherosclcrosis associatcd with a rheological improvement of circulating red blood cells. Kidney Int 63:1881-1887, 2003
PubMed
43) Yang CC, Hsu SP, Wu MS, et al:Effects of vitamin C infusion and vitamin E-coated membrane on hemodialysis-induced oxidative stress. Kidney Int 69:706-714, 2006
PubMed
44) McKiernan SH, Tuen VC, Baldwin K, et al:Adult-onset calorie rcstriction delays the accumulation of mitochondrial enzyme abnormalities in aging rat kidney tubular epithelial cells.Am J Physiol Renal Pbysiol 292:F1751-F1760, 2007
 
45) Keenan KP, Coleman JB, McCoy CL, et al:Chronic nephropathy in ad libitum overfed Sprague-Dawley rats and its early attenuation by increasing degrees of dietary (caloric) restriction to control growth. Toxicol Pathol 28:788-798, 2000
PubMed
46) Cohcn HY, Miller C, Bitterman KI, et al:Calorie restriction promotes mammalian cell survival by inducing the SIRT 1 deacetylase. Science 305:390-392, 2004
 
47) Lamming DW Latorrc-Estcves M, Medvedik O, et al:HST2 mediates SIR2-independent life-span extension by calorie restriction. Science 309:1861-1864, 2005
 
48) Inserra E Romano LA, de Cavanagh EM, et al:Renal interstitial sclcrosis in aging:effects of enalapril and nifedipine. J Am Soc Nephrol 7:676-680, 1996
 

Chapter3 腎障害いかに見出すか

P.119 掲載の参考文献
1) Fairley KE Birch DF:Hematuria:a simple method for identifying glomerular bleeding. Kidney Int 21:105-108, 1982
 
2) Kohler H, WUandel E, Brunck B:Acanthocyturia-a characteristic marker for glomerular bleeding. Kidney. Int 40:115-120, 1991
 
3) 大久典子, 吉田克己, 賀来満夫, 佐藤博:尿中赤血球形態による出血起源鑑別法の位相差および光学顕微鏡での比較. 日本腎臓学会誌 48:401-406, 2006
 
4) Ohisa N, Kanemitsu K, Matsuki R, et al:Evaluation of hematuria using the urinary albumin-to-total protein ratio to differentiate glomerular and nonglomerular bleeding. Clin Exp. Nephrol 11:61-65, 2007
PubMed
5) Ohisa N, Yoshida K, Matsuki R, et al:A comparison of urinary albumin. total protein ratio to phase, contrast microscopic examination of urine sediment for differentiating glomerular and nonglomerular bleeding. Am J Kindey Dis 52:235-241, 2008
 
P.127 掲載の参考文献
1) Lemley W BIouch K, Abdullah I, et al:Glomerular pcrmselectivity at the onsct of nephropathy in type 2 diabetes mellitus. J Am Soc Nephrol 11:2095-2105, 2000
 
2) Gerstein HC, Mann JF, Yi Q, et al; HOPE study Invesrigators:Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286:421-426, 2001
PubMed
3) Arnlov J, Evans JC, Meigs JB, et al:Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals:the Framingham Heart Study. Circulation 112:969-975, 2005
PubMed
4) Klausen KP, Scharling H, Jensen JS, et al:Very low level of microalbuminuria is associated with increased risk ofdeath in subjects with cardiovascular or cerebrovascular diseases. Br J ntern Med 260:231-237, 2006
 
5) Ruggenenti P, Remuzzi G:Time to abandon microalbuminuria Kidney Int 70:1214-1222, 2006
PubMed
6) 柏原直樹, 駒井則夫, 冨田奈留也:糸球体基底膜の蛋白尿への役割. 腎と透析 59:66-71, 2005
 
7) 柏原直樹:CKDと心血管イベント. Annual Review 循環器. 2007, pp94-100
 
8) 柏原直樹, 駒井則夫, 守田吉孝, 冨田奈留也:腎機能調節におけるホルモンおよびペプチドの分子生物学-生合成, 代謝作用-Nitric oxide. 日本臨牀 64:213-216, 2006
 
9) Satoh M, Fujimoto S, Haruna Y, et al:NAD (P) H oxidase and uncoupled nitric oxide synthase are major sources of glomerular supcroxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol 288:F1144-F1152, 2005
PubMed
10) Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, et al:Albuminuria reflects widespread vascular damage. The Stcno hypothesis. Diabetologia 32:219-226, 1989
PubMed
11) 柏原直樹, 佐藤稔:CKD-早期介入の意義と期待効果. 分子病態. 日本臨牀 66:1671-1677, 2008
 
P.134 掲載の参考文献
1) McCullough PA, Adam A, Becker CR, et al; CIN Consensus Working Panel:Risk prediction of contrast-induced nephropathy. Am J Cardiol 98:27K-36K, 2006
PubMed
2) Rihal CS, Textor SC, Grill DE, et al:Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circuintion 105:2259-2264, 2002
PubMed
3) Rule AD, Bergstralh EJ, Slezak JM, et al:Glomerular filtration rate estimated by cystatin C among different clinical presentations. Kidney Int:69:399-405, 2006
PubMed
4) Imai E, Horio M, Nitta K, et al:Estimation of glomerular filtrarion ratc by thc MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 11:41-50, 2007
 
5) Imai E, Horio M, Nitta K, et al:Modification of the Modification of Diet in Renal Disease (MDRI)) Study equation for Japan. Am J Kidney Dis 50:927-937, 2007
 
6) 今井圓裕, 堀尾勝:腎機能の評価. 日本内科学会雑誌 97:921-928, 2008
 
7) Ruggenenti P, Fassi A, Ilieva AP, et al; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators:Prevcnting microalbuminuria in type 2 diabetes. N Engl Bur Med 351:1941-1951, 2004
 
P.140 掲載の参考文献
1) 東原英二 (監):常染色体優性多発性嚢胞腎診療ガイドライン (第2版). 多発性嚢胞腎の全て. インターメディカ, 東京, 2006, pp294-334
 
2) Radermacher J, Chavan A, Bleck J, et al:use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. N Engl J Med 344:410-417, 2001
PubMed
3) Radermacher J, Mengcl M, Ellis S, et al:The renal arterial resistance index and renal allograft survival. N Engl J Med 349:115-124, 2003
 
4) strandncss DE Jr:Duplex imaging for thc detection of renal artery stenosis. Am J Kidney Dis 24:674-678, 1994e
 
5) Textor SC, Glockner JF, Lerman LO, et al:The use of magnetic resonance to evaluate tissue oxygenation in renal artery stenosis. J Am Soc Nephrol 19:780-788, 2008
 
6) Hamano K, Nitta A, Ohtake T, Kobayashi S:Associations of renal vascular resistance with albuminuria and other macroangiopathy in typc 2 diabetic patients. Diabetes Care 31:1853-1857, 2008
 
7) White CJ:Catheter-based therapy for atherosclerotic renal artery stenosis. Circulation 113:1464-1473, 2006
PubMed
8) Prasad PV, Edelman RR, Epstein FH:Noninvasive evaluation of intrarenal oxygenation with BOLD MRI. Circuintion 94:3271-3275, 1996
PubMed

Chapter4 心腎脳連関 : 腎臓病は心血管病, 全身疾患である

P.150 掲載の参考文献
2) Go AS, Chertow GM, Fan D, et al:Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296-1305, 2004
PubMed
3) Fox CS, Larson MG, Leip EP, et al:Predictors of ncw-onset kidncy disease in a community-bascd population. 291:844-850, 2004
 
4) Chen J, Muntner P, Hamm LL, et al:The metabolic syndrome and chronic kidney disease in U. S. adults. Ann In tern. Med 140:167-174, 2004
 
5) Kramer H, Luke A, Bidani A, et al:Obesity and prevalent and incident CKD:the Hypertension Detection and Follow-Up Program. Am J Kidney Dis 46:587-594, 2005
PubMed
6) Brugts JJ, Knetsch AM, Mattace-Raso Fu, et al:Renal function and risk of myocardial infarction in an elderly population:the Rottcrdam Study. Arch Intern Med 165:2659-2665, 2005
 
7) Boaz M, Smetana S, Weinstein T, et al:Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE):randomised placebo-controllced trial. Lancet 356:1213-1218, 2000
PubMed
8) Tepel M, van der Giet M, Statz M, et al:The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure:arandomized, controlled trial:Circulation 107:992-995, 2003
 
9) Perry HM Jr, Miller Jp, Fornoff JR, et al:Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 25:587-594, 1995
PubMed
10) Hillege HL, Girbes AR, de Kam PJ, et al:Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circuintion 102:203-210, 2000
PubMed
11) Bigazzi R, Bianchi S, Baldari D, Campcse VM:Microalbuminuria predicts cardiovascular events and renal insuficiency in patients with esscntial hypertension. J Hypertens 16:1325-1333, 1998
 
12) Mogcnsen CE:Microalbuminuria predicts clinical proteinuria and early mortaliry in maturity-onset diabetes. N Engl J Med 310:356-360, 1984
 
13) Hillege HL, Fidler V, Diercks GE et al;Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group:Urinary albumin cxcretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106:1777-1782, 2002
 
14) Wachtell K, Ibsen H, Olsen MH, et al:Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy:the LIFE study. Ann Intern, Med 139:901-906, 2003
PubMed
15) Gerstein HC, Mann JE Yi Q, et al; HOPE Study Investigators:Albuminuria and risk of cardiovascular events, death and heart failure in diabetic and nondiabetic individuals. JAMA 286:421-426, 2001
 
16) de Jong PE, Curhan GC:Screening, monitoring, and treatment ofalbuminuria:Public health perspectives. J Am Soc Nephrol 17:2120-2126, 2006
 
17) Lemley KV, Blouch K, Abdullah I, et al:Glomerular permselectivity at the onsct of nephropathy in type 2 diabetes mellitus. J. Am Soc Nephrol 11:2095-2105, 2000
 
18) Ruggenenti P, Remuzzi G:Time to abandon microalbuminuria Kidney Int 70:1214-1222, 2006
PubMed
19) Deen WM:What determines glomerular capillary permeability? J Clin Invest 114:1412-1414, 2004
PubMed
20) Modlinger PS, Wilcox CS, Aslam S:Nitric oxide, oxidative stress, and progression of chronic renal failure. Semin Nephrol 24:354-365, 2004
PubMed
21) Fliser D, Kronenberg E Kielstein JT, et al:Asymmetric dimethylarginine and progress on of chronic kidney disease:the mild to moderate kidney diseasc study. J Am Soc Nephrol 16:2456-2461, 2005
 
22) Matsuguma K, Ueda S, Yamagishi S, et al:Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidncy disease. J. Am Nephrol 17:2176-2183, 2006
 
23) Nishiyama A, Yao L, Nagai Y, et al:Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 43:841-848, 2004
PubMed
24) Iseki K, Ikemiya Y, Iseki C, Takishita S:Haematocrit and thc risk of devcloping end-stage renal disease.Nephrol Dial Transplant 18:899-905, 2003
 
25) Chan JC, wat NM, So WY, et al; Asian RENAAL Study Investigators:Renin angiotensin aldosterone system blockade and renal diseasc in patients with type 2 diabctes. An Asian perspective from the RENAAL Study. Diabetes Care 27:874-879, 2004
 
26) Nangaku M:Chronic hypoxia and tubulointerstitial injury:a final common pathway to end, stage renal failure. J Am Soc Nephrol 17:17-25, 2006
PubMed
27) Silverberg D, Wexler D, Blum M, et al:The cardiorenal anaemia syndrome:does it exist? Nephrol Dial Transplant 18 (Suppl 8):viii7-viii12, 2003
 
28) Abramson JL, Jurkovitz CT Vaccarino V, et al:Chronic kidney disease, anemia, and incident strokc in a middle-aged, community-based population:the ARIC Study.kidney Int 64:610-615, 2003
 
l) Stehouwcr CD, Smulders YM:Microalbuminuria and risk for cardiovascular disease:Analysis of potential mechanisms. JAm Soc Nephrol 17:2106-2111, 2006
 
P.157 掲載の参考文献
1) Go AS, Chertow GM, Fan D, et al:Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296-1305, 2004
PubMed
2) Keith DS, Nichols GA, Gullion CM, et al:Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 164:659-663, 2004
 
3) Roberts MA, Hare DL, Ratnaike S, Ierino FL:Cardiovascular biomarkers in CKD:pathophysiology and implications for clinical management of cardiac disease. Am J Kidney Dis 48:341-360, 2006
PubMed
4) Inoue H, Fujiki A, Origasa H, et al:Prevalence of atrial fibrillation in the general population of Japan:An analysis based on periodic health examination. Int J Cardiol; Epub 2008 Aug 6
 
5) Iguchi Y, Kimura K, Kobayashi K, et al:Relation of atrial fibrillation to glomerular filtration rate. Am Bur Cardiol 102:1056-1059, 2008
 
6) Asselbergs FW, Van den Berg MP, Diercks GE et al:C-reactive protein and microalbuminuria are associated with atrialfibrillation. Int J Cardiol 98:73-77, 2005
 
7) Chung MK, Martin DO, Sprecher D, et al:C-reactive protein elevation in patients with atrial arrhythmias. inflammatory mechanisms and persistcnce of atrial fibrillation. Circulation 104:2886-2891, 2001
 
8) Frustaci A, Chimenti C, Bellocci E et al:Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 96:1180-1184, 1997
PubMed
9) Goicocchea M, de Vinuesa SG, Lahera V, et al:Effects of atorvastatin on innammatory and fibrinolytic parameters in patients with chronic kidney disease. J. Am Soc Nephrol 17 (12Suppl 3):S231-S235, 2006
 
10) Hillege HL, Girbes AR, de Kam PJ, et al:Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circuilcution 102:203-210, 2000
PubMed
11) Kottgen A, Russell SD, Loehr LR, et al:Reduced kidncy function as a risk factor fbr incident heart failure:the atherosclerosis risk in communities (ARIC) study. J.Am Soc Nephrol 18:1307-1315, 2007
 
12) Klein IH, Ligtcnberg G, Neumann J, et al:sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol 14:3239-3244, 2003
 
13) Irie E Iso H, Sairenchi T, et al:The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int:69:1264-1271, 2006
 
14) Nakayama M, Metoki H, Terawaki H, et al:Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population-the Ohasama study. Nephrol Dial Tranplant 22:1910-1915, 2007
 
15) Wannamethec SG, shapcr AG, Perry IJ:serum creatinine concentration and risk of cardiovascular disease:a possible marker for increased risk ofstroke. Stroke 28:557-563, 1997
 
16) Perkovic V, Ninomiya T, Arima H, et al:Chronic kidney discase, cardiovascular events, and the effects of perindopril-based blood pressure lowering:data from the PROGRESS study J Am Soc Nephrol 18:2766-2772, 2007
 
17) 熊谷裕生, 鈴木重伸, 尾田高志:慢性腎臓病は脳卒中のリスクファクターである. 実験治療 690:93-98, 2008
 
18) Kobayashi M, Hirawa N, Yatsu K, et al:Relationship between silent brain infarction and chronic kidney disease. Nephrol Dial Transplant 2008 Aug 12 [Epub ahead of print]
 
19) 伊藤貞嘉:心腎連関研究の課題. 循環器科 63 (2):182-187, 2008
 
P.165 掲載の参考文献
1) Go AS, Chertow GM, Fan D, et al:Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.N Engl J Med 351:1296-1305, 2004
PubMed
2) Keane WF, Eknoyan G:Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE):a position paper of the National Kidney Foundation. Am J Kidney Dis 33:1004-1010, 1999
PubMed
3) Arnlov J, Evans JC, Meigs JB, et al:Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals:the Framingham Heart Study. Circulation 112:969-975, 2005
PubMed
4) Cao JJ, Barzilay JI, Peterson D, et al:The association of microalbuminuria with clinical cardiovascular disease and subelinical atherosclerosis in the elderly:the Cardiovascular Health Study. Atherosclerosis 187:372-377, 2006
PubMed
5) Foley RN, wang C, Collins AJ:Cardiovascular risk factor profiles and kidney function stage in the us general population:the NHANES III study. Mayo Clon Proc 80:1270-1277, 2005
 
6) Muntner P, He J, Astor BC, et al:Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease:results from the atherosclerosis risk in communities study. J Am Soc Nephrol 16:529-538, 2005
PubMed
7) Nieuwdorp M, Mooij HL, Kroon J, et al:Endothelial glycocalyx damage coincides with microalbuminuria in type I diabetes.Diabetes 55:1127-1132, 2006
PubMed
8) van den Berg BM, Spaan JA, Rolf TM, Vink H:Atherogcnic region and diet diminish glycocalyx dimension and increase intima-to-media ratios at murine carotid artery bifurcation. Am J Physiol, Heart Circ, Physiol 290:H915-H920, 2006
PubMed
9) Constantinescu M, vink H, Spaan JA:Endothelial cell glycocalyx modulates immobilization of leukocytes at the endothelial surface. Arterioscler thromb Vasc Biol 23:1541-1547, 2003
 
10) Nieuwdorp M, Meuwese MC, Vink H, et al:The endothelial glycocalyx:a potential barrier between health and vascular disease. Curr Opin Lipidol 6:507-511, 2005
 
11) Pahakis MY, Kosky JR, Dull Ro, Tarbell JM:The role of endothelial glycocalyx componcnts in mechanotransduction of fluid shcar stress. Biochem Biophys Res Commun 355:228-233, 2007
PubMed
12) Stehouwcr CD, Hcnry RM, Dekker JM, et al:Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes:further evidence for a link between microalbuminuria and endothelial dysfunction-the Hoorn Study Kidney Int Suppl:S42-S44, 2004
 
13) Santhanam L, Lim HK, Miriel V, et al:Inducible NO synthase dependent S-nitrosylation and activation of arginasel contribute to age-related endothelial dysfunction. Circ Res 101:692-702, 2007
PubMed
14) Johnson FK, Johnson RA, Peyton KJ, Durante W:Arginase inhibition restorcs artcriolar endothelial function in Dahl rats with salt-induced hypertension. Am j Physiol Regul lntegr Comp. Phydiol 288:R1057-R1062, 2005
 
15) Sabbatini M, Pisani A, Uccello E et al:Arginase inhibition slows thc progression of renal failure in rats with renal ablation. Am J Physiol Renal Physiol 284:F680-F687, 2003
 
16) Kielstein JT, zoccali c:Asymmetric dimethylarginine:acardiovascular risk factor and a uremic toxin coming of age? Am J Kidney Dis 46:186-202, 2005
 
17) valkonen VP, Paiva H, salonen JT, et al:Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358:2127-2128, 2001
PubMed
18) Tatematsu S, Wakino S, Kanda T, et al:Role of nitric oxide-producing and-degrading pathways in coronary endothclial dysfunction in chronic kidney disease. J Am Soc Nephrol 18:741-749, 2007
 
19) Cruthirds DL, Novak L, Akhi KM, et al:Mitochondrial targets of oxidative stress during renal ischemia/ reperfusion. Arch Biochem Biophys 412:27-33, 2003
PubMed
20) xu J, wu Song R et al:Proteasome-dependent degradation of guanosine 5'-triphosphate cyclohydrolase I causes tetrahydrobiopterin deficieny in diabetes mellitus. Circulation 116:944-953, 2007
 
21) Milstien S, Katusic Z:Oxidation of tetrahydrobiopterin by peroxynitrite:implications fbr vascular endothelial function. Biochem Biophys res Commun 263:681-684, 1999
 
22) Alp NJ, McAteer MA, Khoo J, et al:Increased cndothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase I overexpression reduces endothelial dysfunction and atherosclerosis in ApoE-knockout mice. Arterioscler thromb Vasc Biol 24:445-450, 2004
PubMed
23) Taylor NE, Maier KG, Roman RJ, Cowley AW Jr:NO synthase uncoupling in the kidney of Dahl S rats:role ofdihydrobiopterin. Hypertension 48:1066-1071, 2006
 
24) Satoh M, Fujimoto S, Haruna Y, et al:NAD (P) H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with expcrimental diabetic nephropathy. Am J.Physiol Renal Physiol 288:F1144-F1152, 2005
PubMed
25) Ross R:Atherosclerosis-an inflammatory disease.N Engl J Med 340:115-126, 1999
PubMed
26) Silacci P, Desgeorges A, Mazzolai L, et al:Flow pulsatility is a critical determinant of oxidative stress in endothelial cells. Hypertesion 38:1162-1166, 2001
 
27) Inoguchi T, Li P, Umeda E et al:High glucose levcl and free fatry acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD (P) H oxidase in cultured vascular cells. Diabetes 49:1939-1945, 2000
 
28) Fujimoto S, Satoh M, Horike H, et al:Olmesartan amcliorates progrcssive glomerular injury in subtotal nephrectomized rats through suppression ofsuperoxide production.Hypertens 31:305-313, 2008
 
29) Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Study Group:Rosuvastatin to prevent vascular events in men and women with elevated Greactive protein. N Engl J Med 359:2195-2207, 2008
 

Chapter5 包括的な診療の提案

P.176 掲載の参考文献
1) 奥田俊洋:わかりやすい腎臓の構造と機能. 中外医学社, 東京, 2000, pp1-4
 
2) 伊藤貞嘉:腎疾患のとらえかた. 一眼でみるベッドサイドの病態生理. (伊藤貞嘉編) 文光堂, 東京, 2003, pp7-30
 
3) 佐藤武夫, 吉田一成 (監訳):30日で学ぶ水電解質と腎臓病. メディカル・サイエンス・インターナショナル, 東京, 2007, p vii
 
4) 奥田俊洋:わかりやすい水電解質と輸液. 中外医学社, 東京, 2001, pp4-12
 
5) Hostetter TH, Olson JL, Rennke HG, et al:Hyperfiltration in remnant ncphrons:a potentially adverse response to renal ablation. J Am Physiol 41:F85-F93, 1981
 
6) chcn J, Muntner P, Hamm LL, et al:The metabolic syndrome and chronic kidney disease in U. S. adults. Ann Intern Med 140:167-174, 2004
 
7) Ramirez SD McClellan W Port FK, Hsu SI:Risk factors for proteinuria in a large, multiracial, Southeast Asian population. J Am J Kidney 13:1907-1917, 2002
 
8) Tozawa M, Iseki K, Iseki C, et al:Influence of smoking and obesity on the developmcnt of proteinuria. Kidnay Int 62:956-962, 2002
 
9) Ninomiya T, Kiyohara Y, Kubo M, et al:Metabolic syndrome and CKD in a general Japanese population:the Hisayama Study. Am J Kidnay Dis 48:383-391, 2006
 
10) Tomaszewski M, Charchar FJ, Maric C, et al:Glomerular hyperfiltration:a new marker of metabolic risk. Kidney Int 71:816-821, 2007
PubMed
11) Sowers JR:Metabolic risk factors and renal disease. Kidney Int 71:719-720, 2007
PubMed
12) Taal MW, Brenner BM:Predicting initiation and progression of chronic kidney disease:Developing renal risk scores. Kidnay Int 70:1694-1705, 2006
 
13) Taal MW, Brenner BM:Renal risk scores:progress and prospects. kidney Int 73:1216-1219, 2008
PubMed
14) Ncnov VD, Taal MW, Sakharova OV, Brenner BM:Multi-hit nature of chronic renal disease. Curr Opin Nephrol Hypertens 9:85-97, 2000
 
15) Iseki K, Iseki C, Ikemiya Y, Fukiyama K:Risk of developing end-stage rcnal disease in a cohort of mass screening. Kidne Int:49:800-805, 1996
 
16) Yamagata K, Ishida K, Sairenchi T, et al:Risk factors for chronic kidney disease in a community, based population:all-year follow-up study. Kidney Int 71:159-166, 2007
 
17) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編):高血圧治療ガイドライン 2009. ライフサイエンス出版, 東京, 2009
 
18) 日本腎臓学会 (編):CKD 診療ガイド. 東京医学社, 東京, 2007
 
19) Orth SR, Hallan SI:Smoking:a risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients-absence of evidence or evidence of absence? Clin J Am Soc Nephrol 3:226-236, 2008
PubMed
20) Chase HP Garg SK, Marshall G, et al:Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes. JAMA 265:614-617, 1991
PubMed
21) Sawicki PT, Didjurgeit U, Muhlhauser I, et al:Smoking is associated with progression of diabetic nephropathy Diahetes Care 17:126-131, 1994
PubMed
22) Bello AK, de Zeeuw D, El Nahas M, et al:Impact of weight change on albuminuria in the general population. Nephrol Dial Transplant 22:1619-1627, 2007
PubMed
23) 松本博, 中尾俊之:食事療法 生活指導. 日本臨牀 66:1799-1802, 2008
Medical*Online
24) 井関邦敏:CKD患者はどの程度, 運動してよいのでしょうか? 慢性腎臓病 (CKD) 診療ガイダンス. (松尾清一, 今井圓裕 編) メジカルビュー社, 東京, 2008, pp139-141
 
25) 日本腎臓学会企画委員会小委員会「食事療法ガイドライン改訂委員会」:慢性腎臓病に対する食事療法基準2007年版 日腎会誌 49:871-878, 2007
 
26) 松本博, 中尾俊之:食事療法. 診断と治療 96:1493-1498, 2008
Medical*Online
P.184 掲載の参考文献
1) Tozawa M, Iseki K, Iseki C, et al:Blood pressure predicts risk of dcveloping end-stage renal diseasc in men and womcn. Hypertension 41:1341-1345, 2003
 
2) Iseki K, Iseki C, Ikemiya Y, et al:Risk of developing low glomerular filtration rate or elevated serum creatinine in a screened cohort in okinawa, Japan. Hypertens Res 30:167-174, 2007
 
3) Bakris GL Williams M, Dworkin L, et d:Preserving renal function in adults with hypertension and diabetes:aconsensus approach. National Kidncy Foundation Hypertcnsion and Diabetes Executive Committecs Working Group. Am J Kidney Dis 36:646-661, 2000
 
4) Anavekar Ns, McMurray JJ, velazquez EJ, et al:Relation between renal dysfunction and cardiovascuiar outcomes after myocardial infection. N Engl J Med 351:1285-1295, 2004
 
5) Stevens LA, Fares G, Fleming J, et al:Low rates oftesting and diagnostic codes usage in a commercial clinical laboratory:evidence for lack of physician awareness of chronic kidney disease. J Am Soc Nephrol 16:2439-2448, 2005
 
6) De Nicola L, Minutolo R, Chiodini B et al; Target Blood Pressure Levels in Chronic Kidney Disease (TABLE in CKD) Study Group:Global approach to cardiovascular risk in chronic kidney disease:reality and opportunities for intervention. Kidney Int 69:538-545, 2006
 
7) Pickering TG, Hall JE, Appel IJ, et al; subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research:Recommendations for blood pressure measurement in humans and experimental animals:Part 1:blood pressure measurement in humans:a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 45:142-161, 2005
 
8) 小原拓, 大久保孝義, 菊谷昌浩ほか:わが国における家庭血圧測定の現状:外来患者 8,506人の実践と意識家庭血圧測定の現状に関する調査研究. 血圧 13:103-110, 2006
 
9) Ohkubo T, Asayama K, Kikuya M, et al; Ohasama Study:How many times should blood prcssure be measured at home for better prediction of stroke risk-ten-year follow-up results from the Ohasama study:J Hypertens 22:1099-1104, 2004
PubMed
10) Andersen MJ, Khawandi w, Agarwal R:Home blood pressure monitoring in CKD. Am J Kidney Dis 45:994-1001, 2005
PubMed
11) Kikuya M, Hozawa A, Ohokubo T, et al:Prognostic significance of blood pressure and heart rate variabilities:the Ohasama study. Hypertension 36:901-906, 2000
PubMed
12) Petcrson JC, Adler S, Burkart JM, et al:Blood pressure control, proteinuria, and the progression of rcnal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 123:754-762, 1995
 
13) Ibsen H, Olsen MH, Wachtell K, et al:Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients:Iosartan intervention for endpoint reduction in hypertcnsion study. Hypertension 45:198-202, 2005
 
14) Sarafidis PA, Khosla N, Bakris GL:Antihypertcnsive therapy in the presence of proteinuria. Am J Kidney Dis 49:12-26, 2007
PubMed
15) Ueda S, Yamagishi S, Matsumoto Y et al:Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease. Clin Exp Nephrol 11:115-121, 2007
PubMed
16) Bagrov AY, Shapiro JI:Endogenous digitalis:pathophysiologic roles and therapeutic applications. Nat Clin Pract Nephrol4:378-392, 2008
PubMed
17) Wu L, Juurlink BH:Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells. Hypertension 39:809-814, 2002
PubMed
P.193 掲載の参考文献
1) 日本腎臓学会 (編):CKD 診療ガイド. 東京医学社, 東京, 2007
 
2) Brenner BM, Cooper ME, dc Zceuw D, et al; RENAAL Study Investigators:Effects of losartan on renal and cardiovascular outcomes in paticnts with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
 
3) Rodby RA, Rohde RD, Clarke WR, et al:The lrbesartan type II diabetic nephropathy trial:study design and baseline patient characteristics. For the Collaborative Study Group. Nephrol Dial Transplant 15:487-497, 2000
 
4) Parving HH, Lehnert H, Brochner-Mortensen J, et al; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group:The effect of irbcsartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
 
5) Makino H, Haneda M, Babazono T, er al:The telmisartan renoprotective study from incipient nephropathy to overt nephropathy-rationale, study design, treatment plan and baseline characteristics of the incipient to overt:angiotensin ll receptor blocker, telmisartan, Investigation on 1 type 2 Diabetic Nephropathy (INNOVATION) Study. J Int Med Res 33:677-686, 2005
 
6) wright JT Jr, Kusek Jw, Toto RD, et al:Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials 17 (4 Suppl):3S-16S, 1996
 
7) Nishiyama A, Yao L, Nagai Y, et al:Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 43:841-848, 2004; Epub 2004 Feb 9
 
8) Sato A, Hayashi K, Naruse M, Saruta T:Effectiveness of aldosterone blockade in patients with diabetic nephropath. Hypertension 41:64-68, 2003
 
9) chabrashvili T, Kitiyakara c, Blau J:Effects of ANG II type 1 and 2 receptors on oxidative strcss, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol 285:R117-R124, 2003
PubMed
10) Nakao N, Yoshimura A, Morita H, et al:Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE):a randomised controlled trial. Lancet 361:117-124, 2003
PubMed
11) Andersen NH, Mogensen CE:Dual blockade of the renin angiotensin system in diabetic and nondiabetic kidney diseasc.Curr, Hypertens Res 6:369-376, 2004
 
12) 伊藤貞嘉 (編):腎疾患のとらえかた一眼でみるベッドサイドの病態生理. 文光堂, 東京, 2003
 
P.202 掲載の参考文献
1) National Kidney Foundation:K/DOQI dinical practice guidelines for chronic kidney disease:evaluation, classification, and stratification. Am J Kidnay Dis 39 (2 Suppl 1):S1-S266, 2002
 
2) Imai E, Horio M, Yamagata K, et al:Slower decline of glomerular filtration rate in the Japanese general population:a longitudinal 10-year follow-up study.Hmpertens Res 31433-441, 2008
 
3) Klag MJ, whelton PK, Randall BL, et al:Blood pressure and end-stage renal disease in men. N Engl J Med 334:13-18, 1996
 
4) Kriz W Kaissling B:Structural organization of the mammalian kidney. In:The Kidney:Physiology and Pathophysiology. 3rd ed. Seldin DW Giebisch G, eds) Lippincott Williams & Wilkins, Philadelphia, 2000, pp587-654
 
5) Hostetter TH, Olson JL, Rennke HG, et al:Hyperfiltration in remnant nephrons:apotentially adverse response to renal ablation. J Am Soc Nephrol 12:1315-1325, 2001
 
6) Grady RW, Novick AC:Hyperfiltration of renal injury:pathophysiology and clinical implications. Urology 47:273-283, 1996
PubMed
7) White SL, Cass A, Atkins RC, Chadban SJ:chronic kidney disease in thc general population. Adv Chronic Kidney.Ois 12:5-13, 2005
 
8) 日本腎臓学会 日本高血圧学会 (編):CKD (慢性腎臓病) 診療ガイド-高血圧編-. 東京医学社, 東京, 2008
 
9) Schroeder K, Fahey T, Ebrahim S:How can we improve adherence to blood pressure-lowering medication in ambulatory care-Systematic review of randomized controlled trials. . Arch lntern Med 164:722-732, 2004
PubMed
P.210 掲載の参考文献
2) Shoji T, Nishizawa Y, Kawagishi T, et al:Athcrogenic lipoprotein changcs in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis. Atherosclerosis 131:229-236, 1997
 
3) Schaeffner ES, Kurth T, Curhan GC, et al:Cholesterol and the risk of renal dysfunction in apparently healthy men. J. Am Soc Nephrol 14:2084-2091, 2003
 
4) Manttari M, Tiula E, Alikoski T, Manninen V:Effects of hypertension and dyslipidemia on the decline in renal function. HOrpertension 26:670-675, 1995
PubMed
5) National Kidney Foundation:K/DOQI clinical practice guidelines for chronic kidney disease:evaluation, classification, and stratification. J Am Kidney Dis 39(2 Suppl 1):S1-S266, 2002
 
6) 日本動脈硬化学会:動脈硬化性疾患予防ガイドライン 2007年版. 協和企画, 東京, 2007
 
7) Rovin BH, Tan LC:LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int 43:218-225, 1993
PubMed
8) Sabbatini M, Pisani A, Uccello E et al:Atorvastatin improves the course of ischemic acute renal failure in aging rats. J Am Soc Nephrol 15:901-909, 2004
 
9) Bussolati B, Dcregibus MC, Fonsato V, et al:Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway. J Am Soc Nephrol 16:1936-1947, 2005
 
10) Tonelli M, Moye L, Sacks FM, et al;Cholesterol and Recurrent Events Trial Investigators:Effect of pravastatin on loss of renal function in people with moderate chronic renal insuficiency and cardiovascular disease. J Am Soc Nephrol 14:1605-1613, 2003
 
11) Athyros VG, Mikhailidis DP, Papageorgiou AA, et al:The effect of statins versus untreatcd dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. Clin Pathol 57:728-734, 2004
PubMed
12) Baigent C, Landray M, Leaper C, et al:First United Kingdom Heart and Renal Protection (UK-HARP-1) study:biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 45:473-484, 2005
PubMed
13) Wanner C, Krane V. Marz W et al; German Diabetes and Dialysis Study Investigators:Atorbastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238-248, 2005
 
14) Muntner P, Coresh J, Smith JC, et al:Plasma lipids and risk of developing renal dysfunction:the atherosclerosis risk in communities study. Kidney Int 58:293-301, 2000
PubMed
15) Kuemmerle NB, chan W Krieg RJ Jr, et al:Effects of fish oil and alpha-tocophenol in immunoglobulin A nephropathy in the rat. Pediatr Res 43:791-797, 1998
 
16) Hamazaki T, Tateno S, Shishido H:Eicosapentaenoic acid and IgA ncphropathy.Lancet 1:1017-1018, 1984
PubMed
17) Pettersson EE, Rekola S, Berglund L, et al:Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids:aprospective, double-blind, randomized study. Clin Nephrol 41:183-190, 1994
 
18) Yokoyama M, Origasa H, Matsuzaki M, et al;Japan EPA lipid intervention study (JELIS) Investigators:Effects of eicosapentaenoic acid on major coronary events in hypercholestcrolaemic patients (JELIS):a randomised open-label, blinded endpoint analysis. Lancet 369:1090-1098, 2007
PubMed
l) Moorhead JF, chan MK, El-Nahas M, varghese Z:Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2:1309-1311, 1982
 
P.218 掲載の参考文献
1) Go AS, Chertow GM, Fan D, et al:Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 35 1:1296-1305, 2004
 
2) Ninomiya T, Kiyohara Y, Kubo M, et al:Chronic kidney disease and cardiovascular disease in a general Japanese population:The Hisayama Study.Kidney Int 681228-236, 2005
 
3) Iseki K, Ikemiya Y, Iseki C, Takishita S:Haematocrit and the risk of developing end-stage rcnal disease. Nephrol Dial Transplant 18:899-905, 2003
PubMed
4) Sarnak MJ, Levey AS, Schoolwerth AC, et al; American Heart Association Councils on Kidney in Cardiovascular Diseasc, High Blood Pressure Rescarch, Clinical Cardiology, and Epidemiology and Prevention:Kidncy disease as a risk factor fbr development of cardiovascular disease:a statement from the American Heart Association Councils on Kidney in Cardiovascular Discase, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108:2154-2169, 2003
 
5) Iseki K, Kohagura K:Anemia as a risk factor for chronic kidney disease. Kidney, Int Suppl:S4-S9, 2007
PubMed
6) Kuriyama S, Tomonari H, Ybshida H, et al:Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77:176-185, 1997
 
7) Nangaku M:Chronic hypoxia and tubulointerstitial injury:a final common pathway to end-stage renal failure. J Am Soc Nephrol 17:17-25, 2006
PubMed
8) Silverberg DS, Wexler D, Blum M, et al:The interaction between heart failure, renal failure and anemia-the cardio-renal anemia syndrome. Blood . Purif 22:277-284, 2004
PubMed
9) Palazzuoli A, Gallotta M, Iovine F, et al:Anaemia in heart failure:a common interaction with renal insuficiency called the cardio-renal anaemia syndrome. Int J Clin Pract:62:281-286, 2008
 
10) Dahlof B, Devereux RB, Kjeldsen SE, et al; LIFE Study Group:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol. Lancet 359:995-1003, 2002
 
11) Ishani A, Weinhandl E, Zhao Z, et al:Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 45:391-399, 2005
PubMed
12) Drueke TB, Locatelli F,Clyne N, et al; CREATE Investigators:Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355:2071-2084, 2006
PubMed
13) Singh AK, Szczech L, T, mg KL, et al:CHOIR Investigators:Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355:2085-2098, 2006
 
14) 第二次腎性貧血治療ガイドライン作成ワーキンググループ:2008年版日本透析医学会慢性腎臓病患者における腎性貧血治療のガイドライン. 透析会誌 41:661-716, 2008
 
15) Szczech LA, Barnhart Hx, Inrig JK, et al:secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74:791-798, 2008
PubMed

書評

最近チェックした商品履歴

Loading...